Jason Del Vicario Ceapro Inc. CZO-X PAST TOP PICK Sep 18, 2017

They extract beta gluten from oats. Have had some very good earnings growth over the last year. Thinks the stock will continue to do well. They are going to expand their plant which should be coming on soon. He still likes this.

Was a top pick last year and has been consolidating recently. They bounce very hard off the $1.20 level. There is a lot of support at that level. They started a new plant to extract product from oats. There is a lot of demand for their product.

A very high margin business. They do beta glucan that goes into Burt’s Bees, Aveeno etc. It is extracted from oats. This is a small component of a number of their products, but margins are very high. They were getting orders from a few companies in China, which ramped up their earnings. The last quarter wasn’t great. He still likes the company. It is going to be bumpy in terms of earnings.

An extraction technology company which basically extracts compounds from food. They make the key ingredients in Aveeno cream. Has a really nice list of clients and good technology. Last quarter was a little weak, but investors didn’t understand that they are running 2 plants now, so costs were higher than normal. The real problem is that management doesn’t do a good job of telling their story. If they could scale it up, it would be a cash cow and a beautiful thing. They’ll be doing an investor update very soon, so watch for that.

(A Top Pick July 4/16. Down 42.48%.) A biotech company out of Alberta and doing some very, very interesting things. They opened a new plant, and he feels the transition from the old plant to the new one has been bumpy. They’ve thrown up 2 lacklustre quarters in a row, and there really hasn’t been a lot of communication from management. He owns a very small position. If you don’t own, wait on the sidelines until a nice quarter comes out or some sort of guidance from the company.

It is worth holding on to even though it is so frustrating. Their revenues and earnings have dripped not due to the core business, but because they used to get one off contracts for their products and have not have one in several quarters. They may get one tomorrow or in a year. There core business is doing okay. It is hard to say if they are worth the market cap. They have interesting trials going on. If that works out they will do well. There are no analysts covering the stock.

(A Past Top Pick Dec 2/16, Down 59%) He is going to conceded defeat on this one. The revenues and earnings have fallen. The company is not good at communicating.